Moleculin Biotech (MBRX) said Tuesday it received regulatory approval in Ukraine to start recruiting for a phase 3 trial of annamycin plus cytarabine to treat relapsed or refractory acute myeloid leukemia, a type of cancer.
The first 75 to 90 subjects in the trial's part A will receive high-dose cytarabine, or HiDAC, combined with either placebo or various doses of annamycin, the company said.
For part B, roughly 244 additional subjects will receive either HiDAC plus placebo or HiDAC plus the optimum dose of annamycin, up from 240 subjects. Moleculin said the increase in the number of subjects represents the "statistical 'cost' of the additional interim unblinding."
Moleculin Biotech said it remains on track to treat a first subject in the phase 3 trial in Q1.
Shares were down over 16% in recent trading.
Price: 0.59, Change: -0.12, Percent Change: -16.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。